Please assess the completion status of the following clinical trial:

Trial Title: Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic PD.~* Patients with motor fluctuations averaging at least 1 hour daily in the OFF state during the waking hours.~* Patients with a Modified Hoehn and Yahr stage ≤3 in the ON state.~* Patients taking optimised levodopa or dopa decarboxylase inhibitor (DDI) therapy; they must be stable for at least 14 days prior to baseline.~* Patients receiving at least 3 daily doses of levodopa and not more than 8 daily doses of levodopa.~* Patients who have demonstrated the ability to keep accurate 24-hour diaries prior to randomisation.~Exclusion Criteria:~* Patients with a clinically significant or unstable medical or surgical condition that would preclude his/her safe and complete study participation.~* Patients with a clinically significant or unstable vascular disease.~* Patients who have undergone a neurosurgical intervention of PD.~* Patients with severe disabling dyskinesias.~* Patients with a clinically significant psychiatric illness, including a major depression, which compromises their ability to provide consent or participate fully in the study.~* Patients with a Mini Mental State Examination (MMSE) score ≤24.~* Patients with a diagnosis of melanoma or a history of melanoma, or a suspicious lesion.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Azilect® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).